Terms
These Terms of Use were last revised on June 18, 2019.
Please Read These Terms of Use Carefully Before Using This Website.
These Terms of Use (“Terms”) describe the terms and conditions applicable to your use of the Neurogene Inc. (“Neurogene”) website (the “Website”). By using this Website, you represent you are at least 18 years of age and you agree to be bound by and to comply with these Terms. If you do not agree to all of these Terms, do not use this Website. These Terms may periodically change without notice, so you should check these Terms before every attempt to use this Website. When these Terms are changed, the date of the latest revision will appear at the top of this page. Neurogene reserves the right at any time and without notice to change this Website. If you continue to use the Website, you signify your agreement to any revisions to these Terms.
Privacy Notice
On this Website Neurogene may collect personal information about you. Please refer to Neurogene’s Privacy Notice (“Privacy Notice”) for details about how we handle your personal information.
Intellectual Property Rights
All content of this Website is the property of Neurogene and its licensors and is protected by U.S. and foreign copyright, trademark, and other intellectual property laws. This Website may also contain or reference patents, proprietary information, technologies, products, processes, or other proprietary rights of Neurogene and/or other parties. Any company names, trademarks, service marks, trade names, logos, and products displayed on this Website are the property of Neurogene, its affiliates, licensees, licensors, or collaboration partners, and no use of any of the foregoing may be made without Neurogene’s prior written consent. Except as expressly provided in these Terms, nothing contained in this Website grants or shall be construed as granting a license or other rights to you under any patent, trademark, copyright, or other intellectual property of Neurogene or any third party. Unauthorized use of any Neurogene trademark, service mark, logo, design, page header, button icon, or script may be a violation of federal and state trademark laws.
Except for information covered by our Privacy Notice, you should assume that any communication or information you transmit through, to or in connection with the Website will not be private. You authorize Neurogene to treat any such content as non-confidential and non-proprietary, and you grant to Neurogene a royalty-free, irrevocable, perpetual, non-exclusive, transferable, worldwide, sublicenseable license to use, reproduce, incorporate, and otherwise exploit any content of such communications or materials, including any data, comments, questions, suggestions, ideas, concepts, inventions, techniques or know-how disclosed therein, for any purpose including developing, manufacturing or marketing goods or services, and disclosing such content to Neurogene’s affiliates, collaboration partners, and other individuals and entities. By submitting any content, you represent and warrant that: (i) you have all rights necessary to transmit such content and grant the licenses thereto specified herein; (ii) such content will not violate or infringe upon the rights of any third party; and (iii) such content will not contain libelous, defamatory or otherwise unlawful material.
Third-Party Content and Linking Policy
This Website may contain links to websites operated by other parties, as well as articles, photographs, text, graphics, pictures, designs, sound, video, information, and other content or items belonging to or originating from third parties (“Third-Party Content”). Such Third-party Content is not under the control of Neurogene, and Neurogene is not responsible for the content available on any other Internet sites linked to this Website. Such Third-party Content does not imply Neurogene’s endorsement of material on any other site and Neurogene disclaims all liability with regard to your access to such Third-party Content. Should you decide to leave this Website and access or use any Third-party Content, you do so at your own risk and you should be aware that Neurogene’s terms and policies no longer govern. You should review the applicable terms and policies, including privacy and data gathering practices, of any site to which you navigate from this Website.
You must adhere to Neurogene’s linking policy as follows: (i) any link to this Website must be a text-only link clearly marked “Neurogene.com” or “Neurogene website;” (ii) the appearance, position and other aspects of the link may not be such as to damage or dilute the goodwill associated with Neurogene’s names and trademarks; (iii) the link most “point” to neurogenestage.wpengine.com and not to other pages within the Website; (iv) the appearance, position and other attributes of the link may not create the false appearance that your organization or entity is sponsored by, affiliated with, or associated with Neurogene; (v) when selected by a user, the link must display the Website on full-screen and not within a “frame” on the linking website; and (vi) Neurogene reserves the right to revoke its consent to the link at any time and in its sole discretion.
Disclaimers
This Website may be unavailable from time to time for maintenance or other reasons. Neurogene shall have no responsibility for any interruption, delay in operation or transmission, theft or destruction of, unauthorized access to, or alteration of, any content made available via the Website.
THE WEBSITE, INCLUDING ALL CONTENT THEREIN, IS PROVIDED ON AN “AS IS” BASIS. NEUROGENE MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, AND NON-INFRINGEMENT. NEUROGENE MAKES NO WARRANTY AS TO THE ACCURACY, CORRECTNESS, TIMELINESS, COMPLETENESS, CURRENCY, OR RELIABILITY OF ANY CONTENT AVAILABLE THROUGH THIS WEBSITE. YOU ARE RESPONSIBLE FOR VERIFYING ANY INFORMATION BEFORE RELYING ON IT. USE OF THIS WEBSITE AND THE CONTENT AVAILABLE ON THIS WEBSITE IS AT YOUR SOLE RISK. NEUROGENE MAKES NO REPRESENTATIONS OR WARRANTIES THAT USE OF THIS WEBSITE WILL BE UNINTERRUPTED OR ERROR-FREE. YOU ARE RESPONSIBLE FOR TAKING ALL NECESSARY PRECAUTIONS TO ENSURE THAT ANY CONTENT YOU MAY OBTAIN FROM THIS WEBSITE IS FREE OF DELETERIOUS PROGRAM MATERIAL INCLUDING MALWARE, WORMS, VIRUSES, AND OTHER EXECUTABLE CODE. NEUROGENE IS NOT OBLIGED TO UPDATE THE WEBSITE AND MAY DISCONTINUE PROVIDING OR DISTRIBUTING THIS WEBSITE FOR ANY REASON OR NO REASON, WITHOUT PRIOR NOTICE.
Limitation of Liability
YOUR USE OF THIS WEBSITE OR ANY CONTENT ON THIS WEBSITE IS AT YOUR OWN RISK. UNDER NO CIRCUMSTANCES WILL NEUROGENE, ITS AFFILIATES OR ITS OR THEIR DIRECTORS, OFFICERS, EMPLOYEES, AGENTS, SUPPLIERS OR LICENSORS BE LIABLE FOR ANY LOSS OF PROFIT, REVENUE, GOODWILL, BUSINESS OPPORTUNITY OR ANTICIPATED SAVINGS OR LOST DATA, OR FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES, WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF OR IN ANY WAY CONNECTED WITH ACCESS TO OR USE OF OR RELIANCE UPON THIS WEBSITE OR CONTENT ON THIS WEBSITE, OR SITES TO WHICH THIS WEBSITE IS LINKED, EVEN IF NEUROGENE HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, INCLUDING BUT NOT LIMITED TO DAMAGES THAT ARISE IN CONNECTION WITH MISTAKES OR OMISSIONS IN, OR DELAYS IN TRANSMISSION OF, INFORMATION TO OR FROM THE USER, INTERRUPTIONS IN TELECOMMUNICATIONS CONNECTIONS TO THIS WEBSITE OR VIRUSES, WORMS, TROJAN HORSES AND OTHER THREATS THAT MAY INFECT YOUR COMPUTER EQUIPMENT WHETHER CAUSED IN WHOLE OR IN PART BY NEGLIGENCE, ACTS OF GOD, TELECOMMUNICATIONS FAILURE, THEFT OR DESTRUCTION OF, OR UNAUTHORIZED ACCESS TO THIS WEBSITE, OR RELATED INFORMATION OR PROGRAMS.
Governing Law and Severability
This Website is operated by Neurogene from its offices in New York, U.S. The law of the State of New York shall govern these Terms, without reference to its choice of law rules. If any provision of these Terms is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of these Terms shall remain in full force and effect. Any provision of these Terms held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. Any invalid or unenforceable provision of these Terms shall be replaced with a valid and enforceable provision that will achieve, to the extent possible, the economic, business and other purposes of such invalid or unenforceable provision.
Rachel McMinn, Ph.D., is Chief Executive Officer of Neurogene and serves as Executive Chair of the company’s Board of Directors. She founded Neurogene in January 2018 with the mission of developing genetic medicines to improve the lives of neurologically-impaired people and their families. Prior to founding Neurogene, Dr. McMinn served as the Chief Business and Strategy Officer of Intercept Pharmaceuticals, a company dedicated to patients with serious liver disease. Prior to her industry experience, Dr. McMinn was an award-winning biotechnology analyst, with 13 years of experience at firms including Bank of America Merrill Lynch, Cowen, and Piper Jaffray. She graduated from Cornell University magna cum laude with a B.A. and earned her Ph.D. from The Scripps Research Institute and was awarded a Post-Doctoral Miller Fellowship at the University of California, Berkeley.
Christine Mikail, J.D., is President and Chief Financial Officer of Neurogene. In her role, Ms. Mikail leads Corporate Strategy and Business Development, Portfolio Management, Operations, and Finance. Ms. Mikail, who joined Neurogene in 2019, brings over two decades of experience supporting biotechnology and pharmaceutical companies in corporate strategy and business development, operations, legal and finance capacities. Prior to Neurogene, Ms. Mikail was Chief Administrative Officer and Head of External Business Development/Alliance Management and General Counsel at Axovant Sciences, Inc., where she was an integral member of the team that raised $362 million in the company’s IPO. Prior to joining Axovant, she held a variety of senior executive positions at NPS Pharmaceuticals, Inc., Dendreon Corporation, Eli Lilly and Company, and ImClone Systems. Ms. Mikail developed her life sciences focus as a corporate and securities lawyer at Reed Smith and WilmerHale. Ms. Mikail graduated cum laude with a B.A. from Rutgers University and earned her J.D. from Fordham University School of Law in 
Andrew Mulberg, M.D., serves as Senior Vice President, Regulatory Affairs, Quality Assurance, and Quality Control at Neurogene. Dr. Mulberg is a pediatric gastroenterologist with nearly 30 years of experience and has a strong passion for helping bring important new medicines to market for patients with devastating rare diseases. In his role at Neurogene, he provides strategic leadership and direction for regulatory and quality activities. Prior to joining Neurogene, Dr. Mulberg led global regulatory affairs for Amicus Therapeutics and held various roles of increasing responsibility within global drug development and medical affairs at Johnson & Johnson. In addition to Dr. Mulberg’s biotechnology and pharmaceutical experience, he spent six years as the Division Deputy Director in the Division of Gastroenterology and Inborn Errors Products at the U.S. FDA. He received his B.A. from Columbia University and his M.D. from Mount Sinai School of Medicine. Dr. Mulberg also previously served as Attending Physician and Fellowship Director of Gastroenterology and Hepatology at Children’s Hospital of Philadelphia. He is currently an adjunct Professor of Pediatrics at the University of Maryland Medical Center, and Chairman of the Medical Advisory Board Go4 the Goal foundation, a pediatric cancer advocacy 501(c)(3) organization.
Stuart Cobb, Ph.D., is Chief Scientific Officer at Neurogene. Dr. Cobb, who joined Neurogene in 2019, brings to the team more than 20 years of experience in translational neuroscience. He leads Neurogene’s scientific research, the development of scientific strategy to support the company’s existing and growing gene therapy portfolio, and efforts to identify novel technologies that complement Neurogene’s pipeline. In addition to his role at Neurogene, Dr. Cobb also leads a research team at the University of Edinburgh, where he is Professor of Translational Neuroscience at Simons Initiative in the Developing Brain and Centre for Discovery Brain Sciences. Prior to his work at Neurogene, Dr. Cobb was a Caledonian Research Fellow and led an academic research laboratory at the University of Glasgow. His research has focused on developing novel genetic treatments for brain disorders based on a deep understanding of the molecular and cellular pathology. Dr. Cobb’s work has been published in leading journals and includes seminal work on the inherent reversibility of neurological features in neurodevelopmental disease. Dr. Cobb has a B.Sc. from the University of Glasgow and a Ph.D. in Neuroscience from the University of Oxford.
Donna M. Cochener, J.D., LL.M., is Senior Vice President and General Counsel of Neurogene. She is a seasoned legal and executive professional with over two decades of experience in corporate law, governance, and executive leadership across the biotechnology and financial services sectors. Prior to joining Neurogene, Ms. Cochener held the roles of Interim Chief Executive Officer and General Counsel at Neoleukin Therapeutics, where she led the company through its merger with Neurogene in December 2023. Her earlier career includes serving as Senior Vice President and Deputy General Counsel at HomeStreet, Inc., the parent company of HomeStreet Bank, where she was primarily responsible for securities reporting and compliance, corporate governance, and led various transactions including mergers and acquisitions. Ms. Cochener was previously a partner at Davis Wright Tremaine LLP in Seattle, and also held associate positions at Heller Ehrman LLP, Riddell Williams P.S., and Perkins Coie LLP.
Julie Jordan, M.D., is Chief Medical Officer at Neurogene. Dr. Jordan brings over 20 years of industry and clinical expertise involving the design and execution of global clinical trials across multiple development areas, including gene therapy and central nervous system disorders. Before joining Neurogene, she was Chief Medical Officer at Homology Medicines, where she was responsible for leading clinical development and operations, leading regulatory interactions and supporting translational research programs for the company’s pipeline of gene therapy and gene editing candidates for rare diseases. She previously held global leadership roles of increasing responsibility at Cerevel Therapeutics, Avanir Pharmaceuticals and Teva Pharmaceutical Industries. Prior to her industry experience, Dr. Jordan was a practicing physician for 10 years and previously served as Clinical Instructor of Medicine at Harvard Medical School and in the Department of Medicine at Massachusetts General Hospital (MGH). She holds an A.B. in Biology from Harvard College and an M.D. from Harvard Medical School and completed her residency in Internal Medicine at MGH, Harvard Medical School.
Arvind Sreedharan serves as Senior Vice President, Business Operations at Neurogene. Mr. Sreedharan, who leads business operations at Neurogene, has over three decades of commercial experience in the pharmaceutical and biotechnology industry, including significant experience in CNS disorders and multiple orphan diseases. Prior to Neurogene, he served as Vice President, U.S. Commercial Operations for AveXis, the gene therapy company that developed Zolgensma®, an FDA-approved treatment for spinal muscular atrophy (SMA), which was acquired by Novartis for $8.7 billion. Earlier, Mr. Sreedharan served as Vice President of Marketing at Auspex Pharmaceuticals, a biopharmaceutical company focused on hyperkinetic movement disorders and rare diseases, acquired by Teva Pharmaceutical for $3.5 billion. Before Auspex, he served as Director, Movement Disorders at Lundbeck, where he played an integral commercial role in the successful product launch and management of Xenazine®, the first FDA-approved drug for the treatment of chorea associated with Huntington’s disease. Mr. Sreedharan has supported and partnered with numerous rare disease advocacy groups throughout his career. He previously served on the Huntington’s Disease Society of America Board of Trustees and is currently a member of the Board of Directors for The Huntington Study Group (HSG), the first Huntington’s Disease cooperative therapeutic research organization and a world leader in facilitating high-quality clinical research trials and studies in Huntington’s Disease. Mr. Sreedharan holds a B.A. in both Biology and History from the University of North Carolina.
Ricardo Jimenez serves as Senior Vice President, Technical Operations at Neurogene. Mr. Jimenez has nearly three decades of experience in the pharmaceutical and biotechnology industry, the majority of which has been focused in the gene therapy field. He joined Neurogene in 2018 and during his tenure has led the company’s internal build out of process and analytical development, the CGMP manufacturing facility including its design, manufacturing operations, quality assurance, and quality control supporting viral vector manufacturing from research grade to clinical scale. Prior to his work at Neurogene, Mr. Jimenez was the site head of the Lonza Houston manufacturing facility and played a leading role in establishing Lonza as a leading contract cell and gene therapy manufacturer, including designing and overseeing the construction of the cell and gene therapy facility in Texas. He began his career in gene therapy in 2005 at Introgen Therapeutics, where he was responsible for the validation activities for adenoviral-based products, and subsequently served as Head of Quality at Vivante GMP Solutions, a gene therapy contract manufacturing organization acquired by Lonza in 2010. Mr. Jimenez holds a B.S. in Biomedical Science from Texas A&M University.